EUVIMEDEUVIMED entdecken
Crossref

Targeting TBK1 With GSK8612 Suppresses Kidney and Cardiac Inflammation and Fibrosis in DOCA /Salt Hypertension

Jiamin Huang, Wei Rong, Ling Li, Wenqiang Yu, Shuangquan Chen, Haihui Xie iD, Hua Liang iD

Nephrology · 2026

DOI: 10.1111/nep.70166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology, 2026. Verfasst von Jiamin Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Hypertension, Kidney, Protein Kinase Inhibitors. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Guangdong Medical Scientific Research Foundation, Foshan Science and Technology Innovation Project Incubation and Cultivation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the therapeutic potential of GSK8612, a selective TBK1 inhibitor, against the inflammatory and fibrotic pathological remodeling in the heart and kidneys induced by DOCA/salt hypertension in mice.

Methods

A salt‐sensitive hypertension model was established in male C57BL/6 mice via uninephrectomy followed by DOCA/salt treatment. Hypertensive mice were administered the selective TBK1 inhibitor GSK8612 (1.5 mg/kg, i.p., once every two days) or vehicle for 21 days. Blood pressure was monitored weekly. Renal and cardiac injury were assessed by histopathology, including Hematoxylin and Eosin, Sirius Red, and Masson's trichrome staining. Extracellular matrix deposition was evaluated via Western blot and immunofluorescence. Macrophage‐to‐myofibroblast transition was determined by F4/80 and α‐SMA co‐staining. Inflammatory cell infiltration was evaluated by immunohistochemistry, while cytokine mRNA levels were quantified by RT‐qPCR.

Results

While GSK8612 treatment showed no significant effect on blood pressure in DOCA/salt‐challenged mice, it significantly improved kidney function and attenuated kidney injury compared to DOCA/salt‐treated controls. GSK8612 treatment significantly inhibited myofibroblast accumulation and extracellular matrix deposition in the kidneys and reduced infiltration of inflammatory cells. Furthermore, it effectively inhibited macrophage‐to‐myofibroblast transition in hypertensive nephropathy. Notably, GSK8612 administration also ameliorated DOCA/salt‐induced cardiac inflammation and fibrosis, as evidenced by reduced infiltration of F4/80 + macrophages and decreased fibroblast activation.

Conclusion

Pharmacological inhibition of TBK1 with GSK8612 confers dual organ protection, attenuating both kidney and heart inflammation and fibrosis in a murine model of salt‐sensitive hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesHypertensionKidneyProtein Kinase InhibitorsNephritisMyocardiumMyocarditisAnimalsMaleFibrosisMice, Inbred C57BLDisease Models, AnimalBlood PressureDesoxycorticosterone AcetateSodium Chloride, DietaryMiceMyofibroblasts

Stichwörter der Autor:innen

TBK1cardiacfibrosishypertensioninflammationkidney

Substanzen

Protein Serine-Threonine KinasesTbk1 protein, mouseDesoxycorticosterone AcetateProtein Kinase InhibitorsSodium Chloride, Dietary

Autor:innen und Institutionen

  • The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
  • Department of Anesthesiology, Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan, China.
  • Department of Anesthesiology, The Tenth Affiliated Hospital Southern of Medical University (Dongguan People's Hospital), Dongguan, China.
  • Shenzhen School of Clinical Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
  • Dongguan Key Laboratory of Anesthesia and Organ Protection, Dongguan, China.

ORCID-Profile: Haihui Xie, Hua Liang

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangdong Medical Scientific Research Foundation
  • Foshan Science and Technology Innovation Project Incubation and Cultivation Program

Zitieren

APA

Huang, J., Rong, W., Li, L., Yu, W., Chen, S., Xie, H., & Liang, H. (2026). Targeting TBK1 With GSK8612 Suppresses Kidney and Cardiac Inflammation and Fibrosis in DOCA /Salt Hypertension. Nephrology. https://doi.org/10.1111/nep.70166

Vancouver

Huang J, Rong W, Li L, Yu W, Chen S, Xie H, et al. Targeting TBK1 With GSK8612 Suppresses Kidney and Cardiac Inflammation and Fibrosis in DOCA /Salt Hypertension. Nephrology. 2026. doi:10.1111/nep.70166

BibTeX
@article{Huang2026,
  author = {Huang, Jiamin and Rong, Wei and Li, Ling and Yu, Wenqiang and Chen, Shuangquan and Xie, Haihui and Liang, Hua},
  title = {Targeting TBK1 With GSK8612 Suppresses Kidney and Cardiac Inflammation and Fibrosis in DOCA /Salt Hypertension},
  journal = {Nephrology},
  year = {2026},
  doi = {10.1111/nep.70166}
}
Kostenlos starten →